Apogee Therapeutics (APGE) CEO sells 20,000 shares in pre-set 10b5-1 plan

Rhea-AI Filing Summary

Apogee Therapeutics Chief Executive Officer Michael Thomas Henderson sold 20,000 shares of Common Stock in open-market transactions. The sales occurred on March 11, 2026 at weighted average prices reported as $74.29, $74.83, and $75.86 per share, across multiple trades within disclosed price ranges.

The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2025. Following the reported sales, Henderson directly holds 1,152,987 shares of Apogee Therapeutics Common Stock, indicating he retains a large remaining equity position.

Insider Trade Summary 10b5-1

Net Seller: 20,000 shares ($1,495,605)

Net Sell 3 txns

Insider HENDERSON MICHAEL THOMAS

Role Chief Executive Officer

Sold 20,000 shs ($1.50M)

Type	Security	Shares	Price	Value
Sale	Common Stock	8,363	$74.29	$621K
Sale	Common Stock	8,219	$74.83	$615K
Sale	Common Stock	3,418	$75.86	$259K

Holdings After Transaction: Common Stock — 1,164,624 shares (Direct)

Footnotes (1)

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.525 to $74.520, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.525 to $75.400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.585 to $76.480, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HENDERSON MICHAEL THOMAS

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		S(1)		8,363	D	$74.29(2)	1,164,624	D
Common Stock	03/11/2026		S(1)		8,219	D	$74.83(3)	1,156,405	D
Common Stock	03/11/2026		S(1)		3,418	D	$75.86(4)	1,152,987	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $73.525 to $74.520, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $74.525 to $75.400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $75.585 to $76.480, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Matthew Batters, as attorney-in-fact for Michael Henderson	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Apogee Therapeutics (APGE) CEO Michael Henderson report in this Form 4?

Michael Henderson, CEO of Apogee Therapeutics (APGE), reported selling 20,000 shares of Common Stock in open-market transactions on March 11, 2026. The filing also shows he continues to directly own 1,152,987 shares after these trades.

At what prices did the Apogee Therapeutics (APGE) CEO sell his shares?

The CEO’s sales used weighted average prices of $74.29, $74.83, and $75.86 per share. Footnotes explain each average reflects multiple trades within ranges from $73.525 up to $76.480, with detailed trade data available upon request.

How many Apogee Therapeutics (APGE) shares does the CEO still own after these sales?

After the reported transactions, CEO Michael Henderson directly holds 1,152,987 shares of Apogee Therapeutics Common Stock. This indicates the 20,000 shares sold on March 11, 2026 represent only a small portion of his overall equity position in the company.

Were the Apogee Therapeutics (APGE) CEO’s share sales part of a trading plan?

Yes. A footnote states the transactions were executed under a Rule 10b5-1 trading plan adopted on August 13, 2025. Such plans are pre-arranged trading programs designed to allow insiders to sell shares over time according to preset instructions.

What type of transactions did the Apogee Therapeutics (APGE) Form 4 disclose?

The Form 4 discloses open-market sales of Common Stock by CEO Michael Henderson, coded as “S” transactions. All three entries are non-derivative sales, with no option exercises or derivative conversions reported in this particular filing.

How many total Apogee Therapeutics (APGE) shares did the CEO sell in this filing?

Across three reported transactions on March 11, 2026, the CEO sold an aggregate of 20,000 shares of Apogee Therapeutics Common Stock. The filing’s transaction summary confirms this total share count as net sales, with no offsetting purchases or grants.